๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edmonton
Clinical trial register · Canada

Clinical Trials in Edmonton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 52 Montreal 35 Vancouver 30 Calgary 30 Edmonton 22
Narrow the registerReset
Recruitment status
Phase
Site location
Toronto52 Montreal35 Vancouver30 Calgary30 Edmonton22
All 50 locations
Target enrolment
to

Trials with a site in Edmonton

22 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Calgary, Edmonton, Oshawa, Toronto
2026-05-31
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
Edmonton, Vancouver, Kentville, Barrie, Hamilton, London, Toronto, Montreal
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
Janssen Research & Development, LLC
Phase 3
460
Edmonton, Vancouver, Kentville, London, Mississauga, Toronto, Montreal
2026-05-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Edmonton, Vancouver, Hamilton, London, Oshawa, Toronto, Montreal
2026-04-21
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Edmonton, Vancouver, Kentville, Barrie, London, Oakville, Toronto, Montreal
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Edmonton, Vancouver, Kentville, Barrie, London, Mississauga, Oakville, Toronto
2025-10-01
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Edmonton
2024-09-19
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
Edmonton, Toronto
2024-06-07
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
684
Calgary, Edmonton, Surrey, London, Newmarket, Toronto, Windsor, Montreal
2023-10-12
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
311
Edmonton, Markham, Peterborough, Richmond Hill, Montreal, Quรฉbec, Saskatoon
2023-10-12
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Calgery, Edmonton, New Westminster, Surrey, Victoria, Halifax, Brampton, Cambridge
2023-04-11
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC
Phase 3
12,523
Calgary, Edmonton, Lethbridge, Medicine Hat, New Westminster, Vancouver, Brandon, Winnipeg
2023-02-15
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Calgary, Edmonton, New Westminster, Vancouver, Victoria, Winnipeg, Dartmouth, Halifax
2022-09-19
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Calgary, Edmonton, New Westminster, Vancouver, Victoria, Winnipeg, Dartmouth, Halifax
2022-07-22
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Calgary, Edmonton, Toronto
2022-03-01
Active, closed
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2
228
Calgary, Edmonton, Toronto, Montreal
2020-12-15
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
Calgary, Edmonton, Toronto, Montreal
2020-09-17
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Calgary, Edmonton, Hamilton, Ottawa, Montreal
2018-04-17
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Calgary, Edmonton, New Westminster, Winnipeg, Barrie, London, Toronto, Waterloo
2018-04-13
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/edmonton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Edmonton that also match the filters currently applied.

How many clinical trials are recruiting in Edmonton?

8 of the 22 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Edmonton), 22 studies
PhaseStudiesRecruitingShare
Phase 313659.1%
Phase 24018.2%
Phase 2/33213.6%
Phase 1104.5%
Phase 1/2104.5%

Most active sponsors

Lead sponsors with the most studies (Edmonton)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC228
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.